Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14647154 | 0.91 | KDM4E (0.52) | HSD17B10GAATSHRPARP1MAPT | |
| SCHEMBL15703264 | 0.90 | HSD17B10 (0.45) | HSD17B10GAATSHRPARP1TNK1 | |
| SCHEMBL14647217 | 0.89 | DRD4 (0.48) | HSD17B10GAATSHRPARP1DRD4 | |
| SCHEMBL14647183 | 0.87 | PARP1 (0.46) | GAATSHRPARP1TNK1MAPT | |
| SCHEMBL14647224 | 0.87 | DRD4 (0.52) | GAAMAPTALDH1A1DRD4DRD3 | |
| SCHEMBL14647158 | 0.87 | MAPT (0.48) | HSD17B10GAATSHRPARP1MAPT | |
| SCHEMBL14647276 | 0.87 | DRD4 (0.54) | HSD17B10GAATSHRPARP1MAPT | |
| SCHEMBL14647115 | 0.85 | PARP1 (0.43) | HSD17B10GAATSHRPARP1DRD4 | |
| SCHEMBL14647230 | 0.84 | KCNH2 (0.48) | TSHRPARP1DRD4DRD3HTR7 | |
| SCHEMBL14647125 | 0.84 | HTR7 (0.52) | HSD17B10PARP1MAPTALDH1A1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2733144-B1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2016-01-06 | — | — | EP | claimed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | claimed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | claimed |
| EP-2733144-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2014-05-21 | — | — | EP | claimed |
| CN-103703002-B | There is PARP and suppress active new compound | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2016-05-11 | — | — | CN | disclosed |
| EP-2733144-B1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| EP-2733144-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2014-05-21 | — | — | EP | disclosed |
| EP-2733144-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2014-05-21 | — | — | EP | disclosed |
| WO-2013008872-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | 参天製薬株式会社 (JP) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | PARP1, PARP11, PARP2 | HSD17B10 3838/4885GAA 3791/4885TSHR 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.